BhaktasharanChimanbhaiPatelMD

Clinical Trials

• ABTECT - Maintenance Start of enrollment: 2023 Jan 16

  Recruiting

  Phase 3

• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 Start of enrollment: 2022 Oct 10

  Recruiting

  Phase 3

• Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis Start of enrollment: 2022 Jan 25

  Active, not recruiting

  Phase 1, Phase 2

• Linerixibat Long-term Safety, and Tolerability Study Start of enrollment: 2020 Jul 14

  Recruiting

  Phase 3

• Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN) Start of enrollment: 2021 Aug 27

  Recruiting

  Phase 3

• Phase 2b Study of GSK4532990 in Adults With NASH Start of enrollment: 2023 Jan 02

  Recruiting

  Phase 2

• Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Start of enrollment: 2022 Dec 06

  Recruiting

  Phase 3

• A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. Start of enrollment: 2023 Jan 27

  Recruiting

  Phase 2

• A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis Start of enrollment: 2023 Aug 31

  Recruiting

  Phase 3

• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis Start of enrollment: 2020 Jun 22

  Active, not recruiting

  Phase 2, Phase 3

• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2022 Sep 13

  Active, not recruiting

  Phase 3

• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2022 Sep 19

  Recruiting

  Phase 2

• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease Start of enrollment: 2018 Apr 13

  Active, not recruiting

  Phase 2, Phase 3

• A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease Start of enrollment: 2023 Dec 13

  Recruiting

  Phase 2

• A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) Start of enrollment: 2023 Oct 25

  Recruiting

  Phase 3

• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis Start of enrollment: 2022 Aug 03

  Recruiting

  Phase 3

• 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) Start of enrollment: 2022 Dec 29

  Active, not recruiting

  Phase 3

• A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Start of enrollment: 2021 Feb 22

  Active, not recruiting

  Phase 3

• Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Start of enrollment: 2021 Sep 14

  Recruiting

  Phase 3

• A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease Start of enrollment: 2018 Apr 09

  Active, not recruiting

  Phase 3

• A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease Start of enrollment: 2015 Sep 16

  Completed

  Phase 2

• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 Start of enrollment: 2018 Mar 21

  Active, not recruiting

  Phase 3

• Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2018 Aug 07

  Terminated

  Phase 2

• Open-label Extension Study of Brazikumab in Ulcerative Colitis Start of enrollment: 2020 Mar 03

  Terminated

  Phase 2

• Open-label Extension Study of Brazikumab in Crohn's Disease Start of enrollment: 2020 Jan 06

  Terminated

  Phase 3

• An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease Start of enrollment: 2018 Dec 07

  Terminated

  Phase 2, Phase 3

• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease Start of enrollment: 2020 Jan 06

  Recruiting

  Phase 3

• Expanded Access Protocol for Patients With Eosinophilic Esophagitis

  Available

• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) Start of enrollment: 2021 Apr 01

  Recruiting

  Phase 3

• Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) Start of enrollment: 2021 Aug 31

  Active, not recruiting

  Phase 2

• CM-101 in PSC Patients -The SPRING Study Start of enrollment: 2020 Oct 01

  Active, not recruiting

  Phase 2

• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2023 Oct 09

  Recruiting

  Phase 2

• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2019 Sep 26

  Active, not recruiting

  Phase 2, Phase 3

• A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Start of enrollment: 2021 Apr 27

  Completed

  Phase 2

• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) Start of enrollment: 2023 Nov 17

  Recruiting

  Phase 3

• Join now to see all